 Alnylams fourth quarter product revenue was more or less as expected, with a fasterbetter-than-expected pace of switching between Onpattro and Amvuttra and further patient growth in Oxlumo and Givlaari. Investors will have multiple clinical read-outs to anticipate this year, including Phase I results from ALN-APP Alzheimers and Phase II results from the zilebesiran hypertension program. 